IRIS - Res&Arch Institutional Research Information System - Research & Archive

DISTRUTTI, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.169
AS - Asia 3.209
EU - Europa 2.392
SA - Sud America 492
AF - Africa 69
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.048
SG - Singapore 1.527
IT - Italia 493
CN - Cina 487
IE - Irlanda 427
BR - Brasile 372
HK - Hong Kong 367
RU - Federazione Russa 362
VN - Vietnam 310
FR - Francia 221
UA - Ucraina 204
DE - Germania 165
FI - Finlandia 111
SE - Svezia 100
GB - Regno Unito 88
KR - Corea 85
BD - Bangladesh 83
TR - Turchia 78
IN - India 69
CA - Canada 57
AR - Argentina 43
MX - Messico 39
AT - Austria 34
PL - Polonia 34
NL - Olanda 33
IQ - Iraq 32
JP - Giappone 27
PK - Pakistan 26
ID - Indonesia 23
ZA - Sudafrica 23
VE - Venezuela 22
CH - Svizzera 21
EC - Ecuador 21
ES - Italia 21
RO - Romania 20
BE - Belgio 18
SA - Arabia Saudita 16
CO - Colombia 13
UZ - Uzbekistan 13
PH - Filippine 12
CZ - Repubblica Ceca 11
MA - Marocco 10
LB - Libano 8
ET - Etiopia 7
MY - Malesia 7
PY - Paraguay 6
CL - Cile 5
GR - Grecia 5
JM - Giamaica 5
AU - Australia 4
IL - Israele 4
LT - Lituania 4
PE - Perù 4
BO - Bolivia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
DK - Danimarca 3
EG - Egitto 3
HN - Honduras 3
KE - Kenya 3
KG - Kirghizistan 3
KW - Kuwait 3
KZ - Kazakistan 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
TH - Thailandia 3
TN - Tunisia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BZ - Belize 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
GP - Guadalupe 2
GT - Guatemala 2
HU - Ungheria 2
JO - Giordania 2
LK - Sri Lanka 2
LY - Libia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
Totale 10.323
Salva come PNG Salva come JPEG
Città #
Singapore 1.168
Chandler 569
San Jose 510
Dublin 422
Hong Kong 367
Ashburn 325
San Mateo 214
Perugia 179
Santa Clara 175
Boardman 148
Dong Ket 148
Beijing 131
Moscow 129
Lauterbourg 107
Altamura 104
Medford 101
Princeton 100
Jacksonville 96
Ann Arbor 87
Los Angeles 87
Lawrence 84
Wilmington 84
Seoul 83
New York 64
Andover 62
Munich 57
Hanoi 46
São Paulo 46
Ho Chi Minh City 44
The Dalles 44
Izmir 38
Helsinki 31
Orem 31
Piscataway 30
Saint Petersburg 29
Tokyo 27
Warsaw 26
Brooklyn 25
Des Moines 24
Houston 23
Columbus 22
Dallas 22
Stockholm 21
Turku 21
Council Bluffs 19
Brussels 18
Frankfurt am Main 18
Timisoara 18
London 17
Rio de Janeiro 17
Toronto 17
Vienna 17
Denver 16
Montreal 16
Chicago 15
Johannesburg 15
Nuremberg 15
Falls Church 14
Mexico City 14
Redwood City 14
Amsterdam 13
Atlanta 13
San Francisco 13
Chennai 12
Phoenix 12
Redmond 12
Rome 12
Seattle 12
Buffalo 11
Den Haag 11
Hefei 11
New Delhi 11
Norwalk 11
San Paolo di Civitate 11
Baghdad 10
Milan 10
Poplar 10
Quito 10
Shanghai 10
Woodbridge 10
Ankara 9
Florence 9
Lahore 9
Manchester 9
Guayaquil 8
Naples 8
Addis Ababa 7
Da Nang 7
Jeddah 7
Vicenza 7
Boston 6
Brasília 6
Brugg 6
Dearborn 6
Haiphong 6
Istanbul 6
Lappeenranta 6
Olomouc 6
Querétaro 6
Riyadh 6
Totale 6.776
Salva come PNG Salva come JPEG
Nome #
The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines 147
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs 147
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 146
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. 141
A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis 141
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. 133
Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential 132
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 130
Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis 122
Effect of bombesin on pancreatic regeneration after subtotal distal pancreasectomy. 120
Antiatherosclerotic effect of farnesoid X receptor. 120
Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities 117
The aryl hydrocarbon receptor (AhR) mediates the counter-regulatory effects of pelargonidins in models of inflammation and metabolic dysfunctions 116
Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 114
a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation 112
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 110
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction 110
BAR501, A SELECTIVE GPBAR1 AGONIST, PROMOTES ADIPOSE TISSUE BROWNING AND AUTOPHAGY AND IMPROVES LIPID METABOLISM AND STEATO-HEPATITIS IN MICE FEED A HIGH FAT DIET 109
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 106
241 - GPBAR1 (TGR5) is a Modulator of Liver Immunity and Reverses Liver Inflammation in a Mouse Models of Acute Hepatitis 106
Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders 106
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases 104
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases 104
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease 103
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation 103
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. 102
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 102
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies 101
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 100
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling 100
The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity 99
Bile Acid Signaling in Inflammatory Bowel Diseases 99
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH 97
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 96
Bile Acids Activated Receptors Regulate innate immunity 96
Inhibition of NF-κB by a PXR-dependent pathwaymediates counter-regulatory activities of rifaximin on innate immunity inintestinal epithelial cells. 95
I peptidil leucotrieni regolano la secrezione di pepsinogeno e la mobilitazione del calcio nelle cellule principali isolate 95
DISCOVERY OF BAR704, A POTENT AND SELECTIVE FXR AGONIST, THAT PROTECTS AGAINST LIVER FIBROSIS 95
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis 95
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy 95
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. 94
The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. 94
Bile Acids Activated Receptors in Inflammatory Bowel Disease 94
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 92
The Pharmacology of Bile Acids and Their Receptors 92
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation 91
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 90
Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity 90
Tu1546 – Gpbar1 is a Modulator of Liver Immunity and Its Agonism Reverses Acetaminophen-Induced Hepatotoxicity by Modulating Recruitment of Liver Macrophages 90
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 90
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 88
Divergent effectiveness of multispecies probiotic preparations on intestinal microbiota structure depends on metabolic properties 88
Bile acids and their receptors in metabolic disorders 88
Bile acids and their receptors in hepatic immunity 87
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 87
Sa1518 – Mechanism of Acute Liver Decompensation Caused by Obeticholic Acid in Cholestasis is Fxr Dependent 87
Nitric oxide-releasing NSAIDs inhibit interleukin 1beta converting enzyme-like cysteine proteases and protect endothelial cells from appopthosis induced by TNFx 86
Mo2014 – Comparative Effects of Bar502, a Dual Fxr and Gpbar1 Agonist, Obeticholic Acid and Ursodeoxycholic Acid in a Rodent Model of Nash 86
Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis 85
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury 85
GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis 85
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 84
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer 84
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) 84
Su1053 - Bar704, a Potent and Selective Fxr Agonist Protects Against Intestinal Fibrosis 83
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice 82
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 82
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease 81
Bile acids and bile acid activated receptors in the treatment of Covid-19 80
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 80
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling 78
VARIABILITY IN INDUSTRIAL PRODUCTION AFFECTS PROBIOTICS ACTIVITY: IDENTIFICATION OF BATCHES OF PROBIOTIC VSL#3 THAT INCREASES INTESTINAL PERMEABILITY AND WORSENS COLITIS IN RODENTS 78
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 76
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 76
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis 76
Tu1738 - The Aryl Hydrocarbon Receptor Mediates Anti-Inflammatory Activities of Natural and Synthetic Pelargonidines in Mouse Models of Colitis 76
Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite 76
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation 75
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders 75
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 74
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. 74
The third gas: H2S regulates perfusion pressure in both theisolated and perfused normal rat liver and in cirrhosis. 74
Chenodeoxycholic Acid: An Update on Its Therapeutic Applications 74
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 73
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. 73
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 72
GPBAR1 (TGR5) LIGATION PROTECTS AGAINST COLITIS DEVELOPMENT BY REGULATING LEUKOCYTE TRAFFINKING AND PROMOTING A IL-10 DEPENDENT SHIFT IN THE M1/M2 PHENOTYPE 72
The identification of farnesoid X receptor modulators as treatment options for non-alcoholic fatty liver disease 72
COXIBs, CINODs and H₂S-releasing NSAIDs: currentperspectives in the development of safer non steroidal anti-inflammatory drugs 71
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases 71
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis 70
Pregnane-X-receptor mediates the anti-inflammatoryactivities of rifaximin on detoxification pathways in intestinal epithelialcells. 70
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 69
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 68
Immunomodulatory functions of FXR 68
Special FX: Harnessing the Farnesoid-X-Receptor to Control Bile Acid Synthesis 67
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 67
Role of Nuclear Receptors in Lipid Dysfunction and Obesity-related Diseases. 66
Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain 66
Immunology of bile acids regulated receptors 65
Totale 9.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.614
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021161 0 0 0 0 0 0 0 0 0 0 0 161
2021/2022785 10 156 9 21 27 12 20 241 9 35 106 139
2022/20231.677 118 323 13 161 143 156 0 100 588 1 57 17
2023/2024647 40 76 27 15 15 4 157 45 42 29 121 76
2024/20251.861 25 157 131 80 195 131 95 138 340 112 288 169
2025/20264.362 287 253 250 524 576 351 748 235 499 394 162 83
Totale 10.611